Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen

A new study examines whether adding Helicobacter pylori stool antigen testing to biennial fecal immunochemical test (FIT) screenings is more cost-effective than using FIT alone for colorectal cancer prevention. The analysis suggests that combining both tests could provide additional health benefits but at a higher cost. This is significant because it helps policymakers decide which screening method offers the best value for healthcare resources, ultimately aiming to reduce colorectal cancer incidence and mortality while managing healthcare costs.